Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Bevurogant on PK of Transporter Probe Cocktail in Healthy Subjects
NCT04590937Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2020
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bevurogant in plaque psoriasis, sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 Extrapolated to Infinity, Area Under the Concentration-time Curve of Rosuvastatin in Plasma Over the Time Interval From 0 Extrapolated to Infinity and 6 more. Started Oct 2020; status: completed.
02
Drugs
bevurogant
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT04590937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04590937.